One of the essential requirements for the utilization of non-viral vectors in tumor therapy is to specifically target the focus site to avoid an off-target effect, which could achieve by binding tumor proteins (ligands) to NPs, for that there are overexpressed receptors in tumor cells (e.g., transferrin receptor, folate receptor, CD44 receptors, and epidermal growth factor receptor) (Candelaria et al., 2021; Nallasamy et al., 2021; Trivedi and Ferris, 2021; Nawaz and Kipreos, 2022). The gene discussed is TFRC; the disease is neoplasm.